Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease.
Levodopa is recommended as a therapeutic approach for patients with the hypokinetic-rigid, Westphal variant of Huntington's disease, but no guidelines are available for the case of nonrespondence to levodopa. In this study, however, we report a 34-year-old woman with this rare variant who showed a clear-cut improvement in motor function and depressive symptoms after treatment with pramipexole, a new dopamine agonist.
Bonelli
Raphael M
RM
Department of Neurology and Psychiatry, Hospital BHB Eggenberg, Graz, Austria. rm.bonelli@nextra.at
Niederwieser
Gerald
G
Diez
Josef
J
Gruber
Andreas
A
Költringer
Peter
P
D000328:Adult; D001545:Benserazide / Q000008:administration & dosage / Q000627:therapeutic use; D052160:Benzothiazoles; D003863:Depression / Q000188:drug therapy; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis / Q000188:drug therapy*; D018476:Hypokinesia / Q000188:drug therapy; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D009127:Muscle Rigidity / Q000188:drug therapy; D000077487:Pramipexole; D012720:Severity of Illness Index; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D052160:Benzothiazoles; D015259:Dopamine Agents; D018491:Dopamine Agonists; D013844:Thiazoles; D007980:Levodopa; D001545:Benserazide; D000077487:Pramipexole